TrialRMD open2025

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes.

Xavier Mariette et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.